Principal Financial Group Inc. Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Principal Financial Group Inc. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLDFree Report) by 20.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 165,220 shares of the biopharmaceutical company’s stock after purchasing an additional 27,534 shares during the quarter. Principal Financial Group Inc. owned 0.06% of Amicus Therapeutics worth $2,344,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Van ECK Associates Corp grew its stake in shares of Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 873 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Amicus Therapeutics by 2.0% in the 3rd quarter. Arizona State Retirement System now owns 60,770 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 1,213 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Amicus Therapeutics by 0.3% in the third quarter. Rhumbline Advisers now owns 416,120 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 1,372 shares in the last quarter. Profund Advisors LLC boosted its stake in shares of Amicus Therapeutics by 1.2% in the third quarter. Profund Advisors LLC now owns 122,207 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 1,478 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Amicus Therapeutics by 4.3% in the third quarter. E Fund Management Co. Ltd. now owns 36,377 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 1,510 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on FOLD. Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Thursday, February 29th. UBS Group decreased their price target on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Guggenheim upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, May 14th. Morgan Stanley decreased their price target on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Friday, May 10th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $17.57.

Check Out Our Latest Stock Report on FOLD

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,928,605.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.80 on Friday. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -20.00 and a beta of 0.80. The business has a fifty day moving average of $10.46 and a 200-day moving average of $11.82. The company has a quick ratio of 2.61, a current ratio of 3.03 and a debt-to-equity ratio of 2.97.

Amicus Therapeutics (NASDAQ:FOLDGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The company had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $111.19 million. During the same period in the previous year, the firm posted ($0.18) earnings per share. The business’s revenue for the quarter was up 27.9% compared to the same quarter last year. As a group, analysts predict that Amicus Therapeutics, Inc. will post -0.19 earnings per share for the current fiscal year.

Amicus Therapeutics Company Profile

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Featured Articles

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLDFree Report).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.